Single-cell RNA sequencing reveals an IL1R2+Treg subset driving immunosuppressive microenvironment in HNSCC
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04015-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Haiyan Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 2…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Tumor Microenvironment, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental research program funding of Ninth People's Hospital affiliated to Shanghai Jiao Tong university School of Medicine, the Project of National Natural Science Foundation of China.
Abstract (Originalsprache)
Regulatory T cells (Tregs) play an immunosuppressive role in tumor microenvironment (TME) in various of cancer types. However, how different Treg subsets influence and effect on head and neck squamous cell carcinoma (HNSCC) remain unclear. Here, using single-cell RNA sequencing (scRNA-seq), we identified an IL1R2+Treg subset which promoted the progression of HNSCC. Via tissue microassay (TMA) and enzyme-linked immunosorbent assay (ELISA), we verified the clinical diagnostic value of the IL1R2+Treg and soluble IL1R2 (sIL1R2). In addition, we constructed tumor-bearing mouse models to explore the antitumor effects of combined targeting IL1R2 and CTLA4. For mechanism, we found IL-1β promoted the expression of IL1R2 and CTLA4 in Tregs, and upregulated CTLA4 though NR4A1 translocation. These results revealed that IL1R2+Treg and serum IL1R2 level had potential diagnostic and prognostic value of HNSCC and combined targeting of IL1R2 and CTLA4 might be an effective strategy to inhibit tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China.
- Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oral and Maxillofacial Surgery, Second Xiangya Hospital of Central South University, Changsha, China.
- Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Clinical Immunology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China. zhangzhen1007@sjtu.edu.cn.
- Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhangzhen1007@sjtu.edu.cn.
Förderung
- Fundamental research program funding of Ninth People's Hospital affiliated to Shanghai Jiao Tong university School of Medicine
- the Project of National Natural Science Foundation of China
Zitieren
APA
Guo, H., Liu, C., Wu, K., Li, Y., Zhang, Z., & Chen, F. (2025). Single-cell RNA sequencing reveals an IL1R2+Treg subset driving immunosuppressive microenvironment in HNSCC. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04015-1
Vancouver
Guo H, Liu C, Wu K, Li Y, Zhang Z, Chen F. Single-cell RNA sequencing reveals an IL1R2+Treg subset driving immunosuppressive microenvironment in HNSCC. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04015-1
BibTeX
@article{Guo2025,
author = {Guo, Haiyan and Liu, Chun and Wu, Kun and Li, Yan and Zhang, Zhen and Chen, Fuxiang},
title = {Single-cell RNA sequencing reveals an IL1R2+Treg subset driving immunosuppressive microenvironment in HNSCC},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04015-1}
}
EUVIMED